Health Care · In Vitro & In Vivo Diagnostic Substances

QDEL QuidelOrtho Corp SEC Filings & Insider Trading Activity 2026

company
CIK 190632499 filings
Russell 2000

QDEL at a glance

QuidelOrtho Corp (QDEL, SEC CIK 1906324) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as October 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 28, 2025 (FY2025), QuidelOrtho Corp (QDEL) reported revenue of $2.7 billion (down 1.9% from FY2024) and a net loss of $1.1 billion. Diluted EPS was -$16.69.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding QuidelOrtho Corp (QDEL) shares worth $357.0 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.7B
−1.9% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
26 funds
$357.0M · −2 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02 · Item 5.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 28, 2025

Full analysis →

Business Overview

  • Core business model: global diagnostics provider specializing in immunoassay, molecular testing, clinical chemistry, transfusion medicine, and POC solutions
  • Initiated wind-down of U.S. donor screening portfolio (VIP platform, microplate assays) starting Feb 2024, expected substantially complete by mid-2026
  • New emphasis on advancing digital solutions with launch of QuidelOrtho RESULTS MANAGER and planned 2026 releases of automation and informatics products
  • R&D spend $186.2M in 2025, down from $218.7M in 2024, reflecting project phase transitions and continued innovation investment
  • Customer service innovation highlighted by being first medical device company awarded global ISO Excellence Services Label in EMEA region

Risk Factors

  • Legal/regulatory risk: FDA EUA approvals and compliance with anti-bribery and data privacy laws impacting product commercialization and operations
  • Geopolitical/macro risk: April 2025 U.S. tariffs on imports from U.K., Canada, Mexico, China causing incremental supply chain and shipping costs
  • Operational/supply chain risk: Concentration in California facilities near earthquake/fire faults posing disruption risk to manufacturing and product delivery
  • Competitive risk: Distributors developing own competitive products and exclusive agreements with rivals threatening key sales channels
  • Financial risk: Customer concentration with significant revenues from few distributors; loss would materially disrupt sales and financial results

Management Discussion & Analysis

  • Revenue $2,730.2M FY25, down 2% YoY from $2,782.9M; FY24 down 7% YoY from $2,997.8M, COVID-19 product declines primary driver
  • Operating margin approx. 20.1% FY25 (Operating expenses $1,488.9M = 54.5% of revenue), cost of sales 53.3% vs 53.8% in FY24; margin benefit from cost savings initiatives
  • Best segment growth: EMEA revenue up 7% to $360.7M, Adjusted EBITDA up 78% to $82.6M; worst segment: Donor Screening revenue down 54% to $52.6M due to U.S. wind-down
  • Operating cash flow pressures from restructuring charges: Restructuring charges $263.6M in FY25 vs $127.2M in FY24; buybacks/dividends details not provided; capital spending not detailed
  • Outlook cautious: Ongoing COVID/endemic dynamics, competitive pressures, pricing pressures, geopolitical tariffs risks; restructuring and strategic refocus ongoing to improve financials

AI summary of the QDEL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 27, 2026

Management Discussion & Analysis

  • Q3 revenue $618.9M, down 12% YoY from $699.9M
  • Cost of sales margin 53.2% vs 52.1% YoY, implying gross margin 46.8% vs 47.9%
  • Best line Immunohematology $142.0M, flat YoY; worst Donor Screening $1.7M, down 88% from $14.7M
  • Cash $166.4M, down $3.4M; operating cash flow used $124.0M through nine months
  • Outlook: weaker respiratory season may persist; China pricing changes and tariffs remain headwinds, with over $80M annual savings targeted for 2027

Risk Factors

  • No material changes to risk factors since the Annual Report
  • Significant indebtedness, potentially limiting financial flexibility
  • Dependence on product development and commercialization success
  • Healthcare regulatory approvals and compliance requirements
  • Intense competition in in-vitro diagnostics markets

AI summary of the QDEL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 27, 2026 announced
  • Earnings conference call scheduled November 3, 2026 at 2:00 p.m. Pacific Time

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • New operating model organized around Core Diagnostics and Point of Care Diagnostics
  • Jonathan Siegrist appointed Head of Point of Care Diagnostics, Bryan Hanson Head of Core Diagnostics, effective November 9, 2026

Item EX-99.1: Item EX-99.1

  • Q3 revenue $618.9M, down 11.6%, driven by respiratory, China, and U.S. Donor Screening weakness
  • Underlying revenue excluding those businesses grew 2.3% reported and 3.0% constant currency
Filed Sep 23, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Covenant relief through September 30, 2029, signaling elevated leverage or reduced earnings pressure
  • Leverage cap eases to 5.50x through July 2, 2028, then tightens to 4.25x from September 30, 2029
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 FY2026 results covered quarter ended June 28, 2026
  • Press release furnished as Exhibit 99.1, containing the financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q2 revenue $630.9M, up 2.8% reported and 1.9% constant currency, with 6.1% growth excluding China
  • Point of Care revenue $108.2M, up 16.3%, while Labs excluding China grew 9.0%

AI summaries of QDEL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for QDEL

Don't miss the next QDEL filing

  • Alerts as it files. A push when QDEL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut QDEL, by share count.
  • Ask anything. An AI agent that reads every QDEL filing and answers with sources.

QDEL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Siegrist Jonathan PhilipMOct 15, 2026-
Siegrist Jonathan PhilipFOct 15, 2026$13.91
Siegrist Jonathan PhilipMOct 15, 2026-
Bowman Ronald LeeFSep 15, 2026$10.63
Bowman Ronald LeeMSep 15, 2026-
Bowman Ronald LeeMSep 15, 2026-
Hanson Bryan MichaelMAug 15, 2026-
Hanson Bryan MichaelMAug 15, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$2.8B$2.7B
Operating Income--$2.0B-$919.2M
Net Income-$10.1M-$2.1B-$1.1B
Op. Margin--70.5%-33.7%
Net Margin--73.7%-41.5%
Balance Sheet
Total Assets$8.6B$6.4B$5.8B
Equity-$3.0B$1.9B
ROE--68.8%-58.9%
Per Share
EPS$-0.15$-30.54$-16.69
Cash Flow
Operating CF-$83.0M$105.2M
CapEx$209.3M$195.1M$188.2M

Source: XBRL data in QuidelOrtho Corp (QDEL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate QDEL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
QDEL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$357.0M
Q2 202628$709.9M
Q1 202628$650.5M
Q4 202527$1.10B
Q3 202527$1.08B
Q2 202526$1.05B
Q1 202525$903.5M
Q4 202423$938.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 210 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

QDEL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 4, 2026Analysis
8-KNov 3, 2026Analysis-
4Oct 19, 2026--
8-KSep 23, 2026Analysis-
4Sep 17, 2026--
4Aug 18, 2026--
SC 13GAug 13, 2026-
10-QAug 7, 2026Analysis
8-KAug 6, 2026Analysis-
4Jul 16, 2026--
SC 13GJul 8, 2026-
4Jul 2, 2026--
4Jun 29, 2026--
4Jun 29, 2026--
4Jun 29, 2026--
4Jun 29, 2026--
4Jun 29, 2026--
4Jun 29, 2026--
4Jun 29, 2026--
4Jun 29, 2026--
4Jun 29, 2026--
8-KJun 23, 2026Analysis-
8-KJun 16, 2026Analysis-
4Jun 9, 2026-
4Jun 9, 2026-

Related Health Care companies

All Health Care →

QDEL SEC filings: frequently asked questions

Which institutions hold QDEL stock?

As of September 30, 2026, the largest QuidelOrtho Corp (QDEL) holders among the 13F filers tracked by SignalX were BlackRock ($117.4 million), Vanguard Portfolio Management LLC ($38.3 million), Invesco Ltd ($38.0 million), State Street Corp ($31.9 million), Vanguard Capital Management LLC ($31.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was QDEL's revenue in fiscal year 2025?

For the fiscal year ended December 28, 2025 (FY2025), QuidelOrtho Corp (QDEL) reported revenue of $2.7 billion (down 1.9% from FY2024) and a net loss of $1.1 billion. Diluted EPS was -$16.69. The figures come from the XBRL data in the 10-K.

What are the main risks in QDEL's latest 10-K?

In the 10-K filed February 19, 2026, QuidelOrtho Corp (QDEL) flagged: Legal/regulatory risk: FDA EUA approvals and compliance with anti-bribery and data privacy laws impacting product commercialization and operations. Geopolitical/macro risk: April 2025 U.S. tariffs on imports from U.K., Canada, Mexico, China causing incremental supply chain and shipping costs. (AI summary of the Risk Factors section.)

What did QDEL report in its latest 8-K?

QuidelOrtho Corp (QDEL) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Q3 2026 results for quarter ended September 27, 2026 announced.

What are the latest QDEL SEC filings?

QuidelOrtho Corp (QDEL) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on October 19, 2026.

What is QDEL's SEC CIK number?

QuidelOrtho Corp (QDEL)'s SEC Central Index Key (CIK) is 1906324. EDGAR lists every QDEL filing under that number.

Ask anything about QDEL

The research agent reads QDEL's filings, financials, insider trades and 13F holders, then answers with sources.